Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors

References

• Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD, Agarwal N, et al. 2015. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clin Genitourin Cancer. 13(3):e131–e137.
   PubMed Web of Science ®Google Scholar
• Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R. 2012. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. Urol Oncol: Semin Ori I. 30(5):704–710.
   Google Scholar
• Bianchi L, Rossi L, Tomao F, Papa A, Zoratto F, Tomao S. 2013. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. Endocr Relat Cancer. 20(5):R233–R245.
   PubMed Web of Science ®Google Scholar
• Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, et al. 2016. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 78(1):167–171.
   PubMed Web of Science ®Google Scholar
• Buda-Nowak A, Kucharz J, Dumnicka P, Kuzniewski M, Herman RM, Zygulska AL, Kusnierz-Cabala B. 2017. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients. Med Oncol. 34(4):68.
   PubMed Web of Science ®Google Scholar
• Clemons J, Gao D, Naam M, Breaker K, Garfield D, Flaig T. 2012. Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer. 10(4):225–231.
   PubMed Web of Science ®Google Scholar
• Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, Kameda W, Susa S, Oizumi T, Tomita Y, et al. 2012. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Jpn J Clin Oncol. 42(8):742–747.
   PubMed Web of Science ®Google Scholar
• de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP. 2005. (2005) Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther. 78(4):433–438.
   PubMed Web of Science ®Google Scholar
• Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B. 2012. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 104(2):93–113.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Kiyota N, Chayahara N, Suzuki A, Umeyama Y, Mukohara T, Minami H. 2012. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs. 30(3):1055–1064.
   PubMed Web of Science ®Google Scholar
• Garber J, Cobin R, Gharib H, Hennessey J, Klein I, Mechanick J. 2012. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 22(12):995–996.
   Web of Science ®Google Scholar
• Kappers M, van Esch J, Smedts F, de Krijger R, Eechoute K, Mathijssen R, et al. 2011. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab. 96(10):3087–3094.
   PubMed Web of Science ®Google Scholar
• Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plöckinger U, Braun D, Schweizer U, Arnold R, Dörken B, et al. 2010. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 20(11):1209–1214.
   PubMed Web of Science ®Google Scholar
• Kitajima K, Takahashi S, Maeda T, Yoshikawa T, Ohno Y, Fujii M, Miyake H, Fujisawa M, Sugimura K. 2012. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function. Eur J Radiol. 81(9):2060–2065.
   PubMed Web of Science ®Google Scholar
• Kust D, Prpić M, Murgić J, Jazvić M, Jakšić B, Krilić D, Bolanča A, Kusić Z. 2014. Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy. Anticancer Res. 34(6):3177–3184.
   PubMed Web of Science ®Google Scholar
• Lechner MG, Vyas CM, Hamnvik O-PR, Alexander EK, Larsen PR, Choueiri TK, Angell TE. 2018. Hypothyroidism during tyrosine kinase inhibitor therapy is associated with longer survival in patients with advanced nonthyroidal cancers. Thyroid. 28(4):445–453.
   PubMed Web of Science ®Google Scholar
• Lechner MG, Vyas CM, Hamnvik O-PR, Alexander EK, Larsen PR, Choueiri TK, Angell TE. 2018. Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced nonthyroidal cancer patients. Thyroid. 28(4):437–444.
   PubMed Web of Science ®Google Scholar
• Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue T-A, Fujisawa M. 2010. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol. 28(5):515–519.
   PubMed Web of Science ®Google Scholar
• Ohba K, Takayama T, Matsunaga H, Matsushita A, Sasaki S, Oki Y, Ozono S, Nakamura H. 2013. Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid. 23(4):443–448.
   PubMed Web of Science ®Google Scholar
• Pani F, Atzori F, Baghino G, Boi F, Tanca L, Ionta MT, Mariotti S. 2015. Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved? Thyroid. 25(11):1255–1261.
   PubMed Web of Science ®Google Scholar
• Riesenbeck LM, Bierer S, Hoffmeister I, Köpke T, Papavassilis P, Hertle L, Thielen B, Herrmann E. 2011. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. 29(6):807–813.
   PubMed Web of Science ®Google Scholar
• Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM. 2007. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 99(1):81–83.
   PubMedGoogle Scholar
• Sabatier R, Eymard JC, Walz J, Deville JL, Narbonne H, Boher JM, Salem N, Marcy M, Brunelle S, Viens P, et al. 2012. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? Ann Oncol. 23(3):714–721.
   PubMed Web of Science ®Google Scholar
• Sato S, Muraishi K, Tani J, Sasaki Y, Tokubuchi I, Tajiri Y, Yamada K, Suekane S, Miyajima J, Matsuoka K, et al. 2010. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J. 57(10):873–880.
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC. 2011. Hypothyroidism in patients with renal cell carcinoma. Cancer. 117(3):534–544.
   PubMed Web of Science ®Google Scholar
• Sella A, Hercbergs A, Hanovich E, Kovel S. 2012. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma? Chemotherapy. 58(3):200–205.
   PubMed Web of Science ®Google Scholar
• Shah D, Shah R, Morganroth J. 2013. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf. 36(6):413–426.
   PubMed Web of Science ®Google Scholar
• Shinohara N, Takahashi M, Kamishima T, Ikushima H, Otsuka N, Ishizu A, Sazawa A, Kanayama H, Nonomura K. 2011. The incidence and the mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer. 104(2):241–247.
   PubMed Web of Science ®Google Scholar
• Shu M, Zai X, Zhang B, Wang R, Lin Z. 2016. Hypothyroidism side effect in patients treated with sunitinib or sorafenib: clinical and structural analyses. Plos One. 11(1):e0147048.
   PubMed Web of Science ®Google Scholar
• Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. 2009. Hypothyroidism related to tyrosine kinase inhibitors: An emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 6(4):219–228.
   PubMed Web of Science ®Google Scholar
• Yavuz S, Apolo AB, Kummar S, del Rivero J, Madan RA, Shawker T, Reynolds J, Celi FS. 2014. Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. Thyroid. 24(8):1223–1231.
   PubMed Web of Science ®Google Scholar